Biotech/medical – Lifeboat News: The Blog

Mar 29
2026

Seven subsets, two fates: mouse γδ T cells in cancer immunity

Mouse γδ T cells in cancer immunity.

Mouse γδ T cells are not all the same; rather, they comprise seven subsets that influence progression in several cancer types.

Antitumor γδ T cell subsets can be tissue-resident or circulating cells, which generally rely on glycolysis for energy production, and they mediate cancer cell death via interferon-gamma or orchestration of antitumor immunity.

Protumor γδ T cell subsets use lipids for energy production, and they promote primary tumor growth and metastasis through the production of interleukin17A to modulate the behavior of myeloid cells sciencenewshighlights ScienceMission https://sciencemission.com/Seven-subsets,-two-fates

The importance of γδ T cells in cancer, as defenders against tumorigenesis, was established more than 2 decades ago. Since that time, research using mouse models of cancer has brought to light a nonuniform view of tumor-associated γδ T cells by providing granularity into the role of individual γδ T cell subsets in specific cancer types. In this review, we discuss data that highlight the unique contributions of Vγ1+, Vγ4+, Vγ5+, Vγ6+, and Vγ7+ cells throughout cancer progression. We delve into their responses to tumors, including both protective and pathogenic functions. We examine how the mechanisms by which these mouse immune cell subsets shape tumor development and spread can be exploited for therapeutic purposes in people with cancer.

Mar 29
2026

New Carbon Nanotube Coating Could Supercharge 6G Technology

Ultrathin nanotube films absorb terahertz waves, boosting 6G performance and enabling advanced shielding and medical applications. Researchers at Skoltech, working with colleagues from KTH Royal Institute of Technology in Sweden, have developed a key technology that could support future 6G commun

Mar 28
2026

Thymic health consequences in adults

Assessing thymic function and health has highlighted the lifelong importance of the thymus as an organ that could be targeted to improve health outcomes, protect against disease and promote healthy ageing.

Mar 28
2026

How human neurons on a chip learned to play Doom

Cortical Labs says the stunt points toward a new kind of low-power computing—and perhaps a new way to study neurological drugs

Mar 28
2026

AI Designed Peptides Could Cure… EVERYTHING. LigandForge Is Here

LigandForge generates 150,000 peptide drug candidates in 3 minutes — a million times faster than existing methods, unlocking a tsunami of possible treatments.

A man with no medical background used ChatGPT, AlphaFold, and Grok to design a custom mRNA cancer vaccine for his dying dog — and her biggest tumor shrank 75%.

Meanwhile, scientists discovered a single protein that literally spreads aging through your bloodstream. These stories are each incredible on their own. But the big story is the implications for curing aging.

In this deep dive, I break down how these three breakthroughs fit together, what peptides and mRNA vaccines actually are (and how they’re different), and why this moment might be the most important inflection point in the history of drug design.

The age of custom AI cures isn’t coming. It’s here.

HUME BODY POD DISCOUNT UP TO 50% OFF:

Continue reading “AI Designed Peptides Could Cure… EVERYTHING. LigandForge Is Here” | >

Mar 28
2026

Ancient DNA finds 15,800-year-old dogs in Anatolia, buried like humans

Evidence of some of the earliest dogs has been identified at two University of Liverpool/British Institute at Ankara archaeological excavation projects in central Anatolia, Turkey. Shedding new light on the development and spread of early domestic dogs, the findings are documented in two papers published in Nature.

Providing fascinating insights into dogs’ relationships with people and their rapid spread across Europe and Anatolia, the work involved zooarchaeologists from University College London, University of Liverpool and based in Turkey and ancient DNA and isotope teams from the Natural History Museum, the Universities of Oxford and York, the Francis Crick Institute, and LMU Munich.

Two of the key excavation sites used are led by the University of Liverpool’s Professor Douglas Baird—Pınarbaşı excavated with Karaman museum and Boncuklu excavated with co-directors Professor Fairbairn, University of Queensland and Associate Professor Mustafaoĝlu, Ankara Hacı Bayram Veli University. Together, the sites span the transition from the Epipaleolithic (latest Paleolithic) to early Neolithic dated 16,000 to 10,000 years ago.

Mar 28
2026

A poorly “cleaned” brain increases the risk of psychosis

A new study from the University of Geneva points to the brain’s waste-clearance system — the glymphatic system — as a possible piece of the psychosis puzzle. In people with 22q11.2 deletion syndrome, a high-risk genetic condition, researchers found developmental differences in an MRI-derived marker linked to glymphatic function, along with associations to hippocampal excitation/inhibition balance and psychosis vulnerability.

A team from UNIGE shows that early alterations in the brain’s clearance system could contribute to vulnerability to psychosis.

How can we explain the onset of psychotic symptoms characteristic of schizophrenia? Despite their major and often irreversible impact on intellectual abilities and autonomy, the biological mechanisms that precede their emergence remain poorly understood. A team from the Department of Psychiatry at the Faculty of Medicine and the Synapsy Center for Neuroscience Research in Mental Health at the University of Geneva (UNIGE) provides new insight into this question. Early dysfunction of the glymphatic system, the network responsible for removing waste from the brain, could be a key vulnerability factor. This research has been published in Biological Psychiatry: Global Open Science.

Hallucinations and delusions are among the characteristic psychotic symptoms of schizophrenia spectrum disorders, which may also be accompanied by social withdrawal and cognitive decline. These disorders, considered neurodevelopmental conditions, most often emerge during adolescence or early adulthood and have an estimated prevalence of 0.5–3% in the general population.

Mar 28
2026

Understanding protein motion could greatly aid new drug design

For many people, “protein” is the key element of a food order. However, beyond the preferred choice of meats or plant-based alternatives, proteins encompass a large class of complex biomolecules whose chemical structure is encoded in our genes. Proteins have critical functions in living cells; they help repair and build body tissues, drive metabolic reactions, maintain pH and fluid balance, and keep our immune systems strong.

To perform their important functions, many proteins have a dynamic molecular structure capable of adopting multiple conformations. For a long time, scientists have suspected that proteins don’t change shape at random. Instead, they seem to move according to deep, slow rhythms—like a building that sways gently in the wind rather than shaking violently.

Those slow rhythms guide how a protein bends, twists, and shifts between its different forms. If one could understand those rhythms, one might be able to predict—and even hurry along—the protein’s movements.

Mar 27
2026

Energy crisis drives T cells to exhaustion in tumors

The immune system’s killer T cells do a commendable job of detecting and destroying cancer cells. But the harsh environment at the heart of tumors often saps them of their vitality, pushing them into a state of permanent lassitude called “terminal exhaustion.” The phenomenon accounts for why so many tumors resist routine immune clearance and even cancer immunotherapies devised to stimulate their lethal capabilities.

Terminal exhaustion is characterized by an accumulation of dysfunctional mitochondria—the bean-shaped energy generators in cells—and extensive genetic reprogramming that stalls proliferation and hobbles the cell-killing weaponry of T cells. Yet how mitochondrial dysfunction is linked to genetic reprogramming in the cells was unclear. No longer. Researchers in the journal Nature show that how the accumulation of useless mitochondria is linked to T cell exhaustion through a complex series of subcellular processes.

The researchers report in their paper that the glut of dysfunctional mitochondria enhances the activity of a cellular protein digesting machine, known as the proteasome, in T cells. The activated proteasome, they show, preferentially degrades mitochondrial heme-containing proteins.

As might be expected, this bias leads to quite the buildup of heme in the cells, resulting in the generation of a functionally distinct form of the molecule referred to as “regulatory heme,” which zips into the nucleus through a transporter named PGRMC2. There it binds to a transcription factor, a protein that regulates gene expression, causing its degradation. This kicks off a series of events that culminates in the activation of genetic programs known to induce terminal exhaustion.

The researchers show that genetic disruption of PGRMC2 abrogates this effect, keeping anti-tumor T cells in a functionally vibrant state, suggesting it is a potential drug target for the enhancement of T cell-activating cancer immunotherapies.

The researchers also examined how the pharmacological inhibition of the proteasome with an existing leukemia therapy, bortezomib, might affect CAR-T cells. Like bortezomib, CAR-T therapy is currently used to treat B cell acute lymphoblastic leukemia (B-ALL).

“We found that the transient and low-dose addition of bortezomib to CAR-T cell cultures during manufacturing reduces exhaustion-associated programs in the cells and induces durable reprogramming of their gene expression patterns to maintain them in a proliferative and functionally vibrant state,” said the author. ScienceMission sciencenewshighlights.

Continue reading “Energy crisis drives T cells to exhaustion in tumors” | >

Mar 27
2026

Mitochondria Delivery Method Rescues Parkinson’s in Mice

Scientists used red blood cells as membrane donors to encapsulate healthy mitochondria and send them into diseased cells, achieving improvements across multiple models and conditions [1].

The delivery problem

Mitochondrial diseases are a diverse group of disorders that arise when mitochondria malfunction. They are often caused by mutations in mitochondrial DNA (mtDNA) itself or in nuclear genes encoding mitochondria-related proteins.